P706 Patient knowledge towards biological treatment in inflammatory bowel diseases: a cross-sectional survey
M. Wiśniewska-Jarosińska*1, M. Włodarczyk2, A. Gąsiorowska1, J. Fichna3, A. Sobolewska-Włodarczyk1
1Medical University of Lodz, Department of Gastroenterology, Lodz, Poland, 2Medical University of Lodz, Department of General and Colorectal Surgery, Lodz, Poland, 3Medical University of Lodz, Department of Biochemistry, Lodz, Poland
Previously, it has been demonstrated in many chronic conditions, including inflammatory bowel diseases (IBD), that better patient knowledge about pathology and treatment improves the course and management of the disease. The aim of this study was to assess the actual knowledge of IBD patients' about the risks and benefits associated with biologic therapies, patients experience with therapy, patients awareness about therapy availability, and expectations of ideal biological therapy.
The study was conducted in collaboration with Polish IBD Patients Association in the period from February 2018 to May 2018. A cross-sectional, internet questionnaire-based study was conducted in 152 IBD patients: 84 patients with Crohn’s disease (CD) and 68 patients with ulcerative colitis (UC). The questionnaire covers three domains of IBD, including diagnosis, therapeutic options, and disease course.
Selected aspects related to the availability of biological therapy in inflammatory bowel disease patients
Knowledge about the use of biologic therapies in IBD patients in Poland is still unsatisfactory. An immediate need exists for patient and physician education about biological therapies and clinical trials to ensure educated and informed decisions are made about biological drug use.